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 Hospital Radiopharmacy in the UK 
 James  R.  Ballinger 
 The fi rst great expansion in nuclear medicine took place around 1970 with the intro-
duction of the  99 Mo/ 99m Tc generator and kit preparations, allowing convenient on 
site production of radiopharmaceuticals. That being said, I would be remiss if I did 
not begin by mentioning the seminal work of Stephen Garnett (much later my PhD 
supervisor) in development of the  51 Cr EDTA technique for determination of glo-
merular fi ltration rate [ 1 ]. 
 In the early days, hospital radiopharmacy usually fell under the remit of medical 
physics and regulation was somewhat informal. The Medicines Act 1968 was the 
fi rst legislation to classify radiopharmaceuticals as drugs. In the early 1970s, the 
Medicines Control Agency (MCA, later Medicines and Healthcare Products 
Regulatory Agency, MHRA) took an interest in improving the standards for prac-
tice of radiopharmacy but at this point theirs was only an advisory role. An early 
guideline on preparation of radiopharmaceuticals in hospitals was published by the 
British Institute of Radiology in 1975 [ 2 ]. With the loss of Crown Immunity in 
1991, radiopharmacy came under the full scrutiny of the MHRA and standards have 
been continually tightened since then. Indeed, the UK led the world in this, for 
which the world does not thank us. 
 Hospital radiopharmacy is now one of the most heavily regulated specialties 
imaginable. Radiopharmaceuticals are drugs (MHRA) but also radioactive materi-
als (Environment Agency), sources of radioactive exposure (Health and Safety 
Executive), for which patient exposure must be optimized (Care Quality 
Commission) and which must be transported safely (Offi ce of Nuclear Regulation). 
Moreover, these different regulatory agencies can have confl icting requirements. 
For safety of the operator, radioactive materials should be handled under negative 
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air pressure but for safety of the patient these procedures should be under positive 
pressure. For safety of the operator in case of contamination there should be a sink 
nearby, but sterile pharmaceuticals must not be handled anywhere near a sink. One 
issue they all agree on is that disposable gloves and gowns are a good idea. As such 
a specialist area, few of the agency inspectors have full understanding, which can 
lead to disastrous outcomes. A classic case occurred some 15 years ago when an 
MHRA inspector insisted that a radiopharmacy sanitise its kits with chlorine based 
disinfectants rather than the usual alcohol; the next day all the products failed 
because  99m Tc labeling requires reducing conditions but the residual chlorine was an 
oxidant. 
 It is believed that the fi rst hospital radiopharmacy in the UK was established at 
the Liverpool Clinic in the late 1950s. Most radiopharmacies at major teaching hos-
pitals were set up in the early 1970s. Radiopharmacy as a specialty became recog-
nized under the Regional Pharmacists Committee and the fi rst formal meeting of 
radiopharmacists took place on 26 January 1977 at a pub in Cambridgeshire. In 
attendance were Malcolm Frier (Nottingham General Hospital), Stuart Hesslewood 
(City Hospital, Birmingham), Penny Hill (Bristol Royal Infi rmary), Colin Lazarus 
(Guy’s Hospital, London), Bill Little (Royal Liverpool Hospital), and Teresa 
McCarthy (Addenbrooke’s Hospital, Cambridge). The Regional Radiopharmacists 
Subcommittee eventually morphed into the UK Radiopharmacy Group (UKRG) 
under which name it is still going strong ( www.ukrg.org.uk ). UKRG remains a pub-
lic sector organisation (there are no commercial members) with broadly geographi-
cal representation and includes members from PET, IPEM, MHRA, and academia. 
 Since the 1990s the UKRG has held an annual workshop open to the radiophar-
macy community and industry in January at The Beeches conference centre in 
Bourneville, Birmingham. Attendance has grown to about sixty, the capacity of the 
venue. In the mid 1990s, UKRG published the UK Radiopharmacy Handbook, 
which was updated in 2002. Much of the content in the original handbook is now 
easily accessible via the internet, but certain sections remain on the UKRG website 
as Radiopharmacy Information Resources. UKRG has also published guidance 
documents on a variety of issues. 
 Also since the 1990s an annual postgraduate lecture course in radiopharmacy has 
been held at King’s College London under the auspices of the UKRG. Originally set 
up by Tony Theobald (KCL) and Stephen Mather (St Bartholomew’s Hospital, Queen 
Mary University, Cancer Research Campaign), it has latterly been organised by Jim 
Ballinger (KCL, Guy’s and St Thomas’ Hospital). This is open to anyone interested in 
the fi eld and is offered for credit to students on the MSc in Nuclear Medicine Science 
(KCL), MSc in Pharmaceutical Technology and Quality Assurance (PTQA; origi-
nally at the University of Leeds, now at University of Manchester), and the new MSc 
in Clinical Pharmaceutical Science (University of Manchester). Annual attendance 
varies between 20 and 45. UKRG has also co- sponsors with KCL a biannual practical 
course in radiochemical purity testing; laboratory space limits attendance to 20. 
 The UKRG has maintained a database of adverse reactions and product defects. 
For many years annual summaries were published in the European Journal of 
Nuclear Medicine blue pages and the plan is for this tradition to resume. 
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 Throughout the years, UKRG members have played an important role in such 
UK organisations as the British Nuclear Medicine Society (BNMS) and the 
Administration of Radioactive Substances Advisory Committee (ARSAC), as well 
as the European Association of Nuclear Medicine (EANM). The biannual European 
Symposium on Radiopharmacy and Radiopharmaceuticals has been hosted in the 
UK on three occasions. 
 Charles Sampson (Addenbrooke’s Hospital, Cambridge) edited the Textbook of 
Radiopharmacy in 1990. It is now in its fourth edition, edited by Tony Theobald, 
and renamed Sampson’s Textbook of Radiopharmacy in Charlie’s honour. 
 There have been many developments in Positron Emission Tomography (PET) in 
which the UK has played a major role, with the original two PET centres at the 
Hammersmith Hospital and the University of Aberdeen, and the fi rst clinical PET 
centre at Guy’s and St Thomas’ Hospital. However, this development has largely 
been in parallel with hospital radiopharmacy rather than part of it; both fi elds have 
been poorer because of this missed opportunity. 
 The presence in the UK of one of the largest radiopharmaceutical companies, 
Amersham International, now part of GE Healthcare, meant that a number of new 
 99m Tc labeled radiopharmaceuticals were fi rst put into humans in UK nuclear medi-
cine departments. These include cerebral perfusion imaging with  99m Tc HMPAO 
(Ceretec) at the Middlesex Hospital [ 3 ] and Aberdeen [ 4 ], myocardial perfusion 
imaging with  99m Tc tetrofosmin (Myoview), based on chemistry developed at the 
University of Cardiff, also at Aberdeen [ 5 ], and hypoxia imaging with  99m Tc HL91 
(Prognox, never marketed) at Guy’s Hospital [ 6 ]. Mention must also be made of the 
development of cell radiolabeling techniques by the group under the direction of 
Michael Peters at the Hammersmith Hospital, leading to  111 In tropolonate [ 7 ] and 
 99m Tc HMPAO [ 8 ] becoming standard labeling methods worldwide. This is now 
being extended to subpopulations of cells [ 9 ]. Over the last 50 years we have wit-
nessed great changes within the radiopharmaceutical industry, as I have chronicled 
elsewhere [ 10 ]. At times the radiopharmaceutical divisions have suffered as minor 
cogs in the big wheel of a pharmaceutical or chemical company. 
 Within pharmacy, radiopharmacy has suffered by being classifi ed as a technical 
service when in reality it is among the most clinical of specialties. The radiophar-
macy is often embedded in a clinical nuclear medicine department where it is 
impossible to avoid patients even if one wanted to. Where else can one see the full 
gamut — from raw materials to injectible product to clinical results — all within a 
matter of minutes to hours? I’m still amazed every time I see a beating heart on the 
processing monitor. But pharmacy is only one route into radiopharmacy, and the 
lack of a defi ned career path has created problems in recruitment and succession 
planning. Finally in 2013 Health Education England set up a scientist training pro-
gramme in Clinical Pharmaceutical Science which will lead to state registration 
with the Health and Caring Professions Council (HCPC). Finally, formal recogni-
tion of radiopharmacy. 
 In summary, the practice of hospital radiopharmacy has become much more 
tightly controlled over the last 50 years. Ensuring high standards has been expensive 
both in terms of operating and capital costs. Ironically, this has protected NHS 
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radiopharmacies by making the UK unattractive for commercial radiopharmacies. 
But this has also slowed the implementation of new procedures which are virtually 
routine elsewhere; witness the limited availability of  68 Ga labeled peptides in the 
UK. My greatest sadness is that the diversion of human resources to regulatory 
issues has virtually killed hospital based radiopharmaceutical research and develop-
ment in the UK. Despite this, members of the UK community continue to play an 
important role nationally and internationally in advancing the practice of hospital 
radiopharmacy. 
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 James  R.  Ballinger  I retired in 2015 after spending 31 years in clinical radiopharmacy, half of 
that time in Canada, the remainder in the UK. Born in Toronto, I obtained my BSc in Pharmacy 
from the University of Toronto in 1976, followed by an MSc in analytical toxicology. I was then 
persuaded to undertake a 1-year residency in radiopharmacy at Chedoke-McMaster Hospital in 
Hamilton, followed by a PhD in PET radiochemistry, where my project involved synthesis and 
evaluation of  18 F-fl uoronicotine for regional cerebral perfusion studies and investigation of the 
nicotinic acetylcholine receptor. In 1984 I took a position as radiopharmacist at Ottawa Civic 
Hospital where I developed a profi le as an independent researcher. I moved to the Ontario Cancer 
Institute and Princess Margaret Hospital in Toronto in 1990 and continued research in multidrug 
resistance to chemotherapy and hypoxia imaging. In 1999, perhaps unwisely, I migrated against 
the rotation of the earth to take a post at Addenbrooke’s Hospital in Cambridge. My fi nal move was 
in 2003 to Guy’s and St Thomas’ Hospital and King’s College London, where I was involved in 
setting up and teaching on the MSc in Radiopharmaceutics and PET Radiochemistry. I am a fellow 
of the Royal Society of Chemistry. I have published more than 110 peer reviewed scientifi c papers, 
20 invited reviews, 12 book chapters, and have given invited lectures in North America, Europe, 
and Japan. 
 I served lengthy terms as newsletter editor, fi rst for the Canadian Association of 
Radiopharmaceutical Scientists (CARS) and later the UK Radiopharmacy Group, and a shorter 
term as News and Views editor for BNMS. I was chair of the Canadian Society of Nuclear Medicine 
and a member of the radiopharmacy committee of the European Association of Nuclear Medicine, 
the radioactive drugs committee of the British Pharmacopoeia, and the Administration of 
Radioactive Substances Advisory Committee. In the latter role I contributed to two reports on 
future provision of  99m Tc. I represented the UK on a three person delegation to lobby the European 
Parliament during the drafting of the Clinical Trials Regulations. 
 My outside interests include music, theatre, and literature. In my retirement I intend to drink 
less coffee and more wine. 
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